Pro Medicus (ASX:PME) share price higher on Mayo Clinic deal

This high-flying healthcare technology company is ascending again on Thursday…
The post Pro Medicus (ASX:PME) share price higher on Mayo Clinic deal appeared first on The Motley Fool Australia. –

The Pro Medicus Limited (ASX: PME) share price is on the move on Thursday morning following the release of an announcement.

At the time of writing, the health imaging company’s shares are up 1% to $46.75.

This latest gain means the Pro Medicus share price is up 33% since the start of the year.

What did Pro Medicus announce?

This morning Pro Medicus announced that its wholly owned U.S. subsidiary, Visage Imaging, has signed a multi-year research collaboration agreement with healthcare giant Mayo Clinic.

According to the release, the agreement will serve as the framework for collaboration between the two parties to facilitate development and commercialisation in the field of artificial intelligence (AI), leveraging the Visage AI Accelerator platform.

Visage Imaging’s Global CTO, Malte Westerhoff, PhD, said: “Our AI Accelerator program was designed to closely align Visage’s engineering and product development capability with clinical research partners such as Mayo Clinic who have a depth of clinical knowledge and extensive research expertise.”

“It provides a unique set of tools for data de-identification, collection, curation, analysis and ‘path-to-production’ in research projects bringing the efficiency and speed of Visage technology to research, resulting in a unified link between the two domains,” he added.

Dr Westerhoff believes AI will play a major role in the healthcare sector in the future. This is particularly the case in the imaging IT field, which could benefit from the development of innovative AI solutions.

He concluded: “We see AI playing a significant role in healthcare particularly in our field of imaging IT. We have optimized our Visage 7 platform for AI enabling both our own, as well as third-party algorithms to be seamlessly integrated into the clinician’s desktop. We see this research collaboration agreement with Mayo Clinic as another significant piece of our AI strategy, one that has the potential to develop innovative AI solutions that meet well defined clinical goals and ultimately lead to better patient outcomes.”

The post Pro Medicus (ASX:PME) share price higher on Mayo Clinic deal appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!